FDA Accepts UroGen's UGN-103 Application for Bladder Cancer Treatment

Bitget2026/10/19 12:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA accepted UroGen Pharma’s UGN-103 application to treat adults with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer.
The agency set a June 14, 2027, target action date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONEFULLFEED9847629) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA Accepts UroGen's UGN-103 Application for Bladder Cancer Treatment

You may also like

Crypto prices